VITEK 2 AST GP CEFTAROLINE

K141149 · bioMerieux, Inc. · LON · Jun 20, 2014 · Microbiology

Device Facts

• Record ID: K141149
• Device Name: VITEK 2 AST GP CEFTAROLINE
• Applicant: bioMerieux, Inc.
• Product Code: LON · Microbiology
• Decision Date: Jun 20, 2014
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.1645
• Device Class: Class 2

Intended Use

VITEK® 2 Gram Positive Ceftaroline is designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 Gram Positive Ceftaroline is a quantitative test. Ceftaroline has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial. Active in vitro and in clinical infections Staphylococcus aureus (including methicillin-susceptible and -resistant isolates) The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., and clinically significant yeast.

Device Story

VITEK® 2 AST-GP Ceftaroline test card; 64 micro-wells containing premeasured antibiotic concentrations and culture media. Input: isolated bacterial colonies diluted in 0.45-0.5% saline. Operation: VITEK® 2 system automatically fills, seals, and incubates cards; VITEK® 2 Compact uses manual filling/sealing. System monitors growth via optical light detection over incubation period. Output: quantitative MIC value and interpretive category (S, I, R). Used in clinical microbiology laboratories by technicians/microbiologists. Results assist clinicians in selecting appropriate antimicrobial therapy for Gram-positive infections.

Clinical Evidence

Bench testing only. Performance evaluated using fresh and stock clinical isolates and challenge strains. Compared against CLSI broth microdilution reference method (16-20 hours incubation). Results: 97.9% overall essential agreement and 99.2% overall category agreement. Reproducibility and quality control testing demonstrated acceptable results.

Technological Characteristics

Miniaturized broth microdilution card; automated incubation and optical growth monitoring; quantitative MIC determination; compatible with VITEK® 2 and VITEK® 2 Compact systems; standalone laboratory instrument platform.

Indications for Use

Indicated for antimicrobial susceptibility testing of isolated colonies of Staphylococcus aureus (including methicillin-susceptible and -resistant isolates) to determine in vitro susceptibility to Ceftaroline. For use by laboratory professionals in clinical settings.

Regulatory Classification

Identification

A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.

Special Controls

*Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”

Predicate Devices

• VITEK® 2 AST-GP Clindamycin (k122547)

Submission Summary (Full Text)

{0}------------------------------------------------

K/41149

Image /page/0/Picture/1 description: The image shows the logo for bioMerieux. The logo consists of the word "BIOMERIEUX" in a stylized font, with a circular symbol above it. The circle is divided in half, with the left half filled with horizontal lines and the right half solid black. A curved line runs vertically through the center of the circle and the text.

JUN 20 2014 VITEK® 2 AST-GP Ceftaroline

Traditional 510(k) Submission

# 510(k) SUMMARY

# VITEK® 2 AST-GP Ceftaroline

### 510(k) Submission Information:

Submitter's Name: Address:

bioMérieux, Inc.

Charlene Ferrand Regulatory Affairs Officer

314 -731-8630

314-731-8689

21 CFR 866.1645

Product Code LON

595 Anglum Road Hazelwood, MO 63042

Contact Person:

Phone Number:

Fax Number:

Date of Preparation:

April 8th, 2014

VITEK® 2 AST-GP Ceftaroline

Antimicrobial Susceptibility System

VITEK® 2 AST-GP Ceftaroline

### B. Device Name:

Formal/Trade Name:

Classification Name:

Common Name:

VITEK® 2 AST-GP Clindamycin (K122547)

Fully Automated Short-Term Incubation Cycle

## D. 510(k) Summary:

C. Predicate Device:

VITEK® 2 Gram Positive Ceftaroline is designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 Gram Positive Ceftaroline is a quantitative test. Ceftaroline has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.

### Active in vitro and in clinical infections

Staphylococcus aureus (including methicillin-susceptible and -resistant isolates)

The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative microorganisms, Staphylococcus spo., Enterococcus spo., Streptococcus spp. and clinically significant yeast.

The antimicrobial presented in VITEK 2 AST-GP Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK® 2 AST Cards are essentially miniaturized

{1}------------------------------------------------

versions of the doubling dilution technique for determining the minimum inhibitory concentration (MIC) microdilution methodology.

The isolate to be tested is diluted to a standardized concentration in 0.45 - 0.50% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK® 2 automatically fills, seals and places the card into the incubator/reader. The VITEK® 2 Compact has a manual filling and sealing operation. The VITEK® 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antimicrobial contained on the card.

VITEK 2 AST-GP Ceftaroline demonstrated substantially equivalent performance when compared with the CLSI broth microdilution reference method, as defined in the FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Issued August 28, 2009.

The Premarket Notification (510[k]) presents data in support of VITEK® 2 AST-GP Ceftaroline. An external evaluation was conducted with fresh and stock clinical isolates, as well as a set of challenge The external evaluations were designed to confirm the acceptability of VITEK® 2 AST-GP strains. Ceftaroline by comparing its performance with the CLSI broth microdilution reference method incubated at 16 - 20 hrs. The data is representative of performance on both the VITEK® 2 and VITEK® 2 Compact instrument platforms. VITEK 2 AST-GP Ceftaroline demonstrated acceptable performance of 97.9% overall essential Agreement and 99.2% overall category agreement with the reference method. Reproducibility and Quality Control demonstrated acceptable results.

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the text "DEPARTMENT OF HEALTH & HUMAN SERVICES" in bold, uppercase letters. The text is horizontally oriented and appears to be a header or title. The font is a sans-serif typeface, and the overall impression is one of official documentation or signage.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

BIOMERIEUX, INC. CHARLENE FERRAND 595 ANGLUM RD. HAZELWOOD MO 63042-2320

June 20, 2014

Re: k141149

Trade/Device Name: VITEK® 2 AST-GP Ceftaroline (<0.06- ≥4μg/mL) Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility system Regulatory Class: II

Product Code: LON Dated: May 7, 2014 Received: May 8, 2014

Dear Ms. Ferrand:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Parts 801 and 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2-Ms. Ferrand

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

# Uwe Scherf -S for

Sally Hojvat, M.Sc., PhD. Director, Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known) k141149

Device Name

VITEK® 2 AST-GP Ceftaroline ( < 0.06 - ≥4 µg/mL)

### Indications for Use (Describe)

VITEK® 2 Gram Positive Ceftaroline is designed for antimicrobial susceptibility testing of Gram positive microorganisms and is intended for use with the VITEK® 2 and VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK® 2 Gram Positive Ceftaroline is a quantilative test. Ceftaroline has been shown to be active against most strains of the microorganisms listed below, according to the FDA label for this antimicrobial.

### Active in vitro and in clinical infections

Staphylococcus aureus (including methicillin-susceptible and -resistant isolates)

The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant arrobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., and clinically significant yeast.

| Type of Use (Select one or both, as applicable) | |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| <span style="float:left;"> <div style="width:20px; height:20px; border:1px solid black;"></div> </span> Prescription Use (Part 21 CFR 801 Subpart D) | <span style="float:left;"> <div style="width:20px; height:20px; border:1px solid black;"></div> </span> Over-The-Counter Use (21 CFR 801 Subpart C) |

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Ribhi Shawar -S 2014.06.20 11:01:26 -04'00'

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

*An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."